



NZX Release

BLIS announces new board member

Blis Technologies Limited, 28 September 2018, Dunedin, NZ

Blis Technologies Limited (NZX: BLT) advises the appointment of Dr Alison Stewart as an independent director of the company with effect from 28 September 2018.

Dr Stewart brings to the board governance and commercial experience within the international biotech industry. Dr Stewart has held key executive leadership roles in New Zealand and US corporates and understands the drivers for commercial success. Alison has experience with patents, IP protection, new product pipeline and development of strategic partnerships with large international corporations.

Dr Stewart is currently Chief Executive Officer of the Foundation of Arable Research and in previous roles has lead research teams across NZ, Australia and the USA. Alison is a Distinguished Emeritus Professor, Lincoln University, NZ and received a Queens Birthday Honours Companion of the NZ Order of Merit award in 2011.

Chairman Tony Offen said “We are delighted Dr Stewart has agreed to join the board and believe her commercial background underpinned by her academic qualifications will add considerable value to the company.”

The company’s focus remains growing revenues and consumer reach for its branded product range across core markets whilst developing international partnerships that are capable of accelerating growth by leveraging the company’s brand, IP and pipeline opportunities.

The new appointment is the result of a director search undertaken as part the board’s succession planning. The board has determined that Dr Stewart will be an independent director and will support her when formally offering herself for election as director at the next annual shareholders' meeting in July 2019.

About Blis Technologies Ltd

Blis Technologies is the developer of the world’s first advanced oral probiotics. Developed in New Zealand and backed by more than 30 years of research, the BLIS range includes products that support oral, ear, nose and throat health. BLIS probiotics were discovered by Professor John Tagg while working as a researcher at the University of Otago Microbiology Department. BLIS products are sold throughout New Zealand and in Asia, Europe, and USA.

A handwritten signature in black ink, appearing to read "A. Offen", is positioned above the typed name of the signatory.

Tony Offen
Chair
Blis Technologies Limited